European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, MyelomaAugust 22, 2023
FDA approves elranatamab (ELREXFIO™) for relapsed or refractory myelomaAccess, MyelomaAugust 21, 2023
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, MyelomaAugust 14, 2023
Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern EuropeAccess, MyelomaJune 25, 2023
The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, MyelomaAugust 30, 2022
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, MyelomaJuly 28, 2022
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, MyelomaOctober 19, 2021
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosisJune 23, 2021